Tag: Astellas

Astellas Pharma Inc. is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.

Potenza became Subsidiary of Astellas

Astellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three years working together on cancer immunotherapies. The Japanese pharma said the acqu...

Astellas to construct new R&D and manufacturing facilities

Astellas Pharma announced that construction and renovation of new facilities for the research, development and manufacture of new drugs has begun in Toyama and Tsukuba as well as Massachusetts.

Astellas buys British gene therapy company Quethera

Astellas Pharma and Quethera Limited announced that Astellas has acquired Quethera, a gene therapy company, that is focused on developing novel treatments for ocular disorders, such as glaucoma.

Eurofins Scientific seals an outsourcing deal with Astellas

Eurofins Scientific, a global leader in biopharmaceutical products testing services, announces that it has signed an outsourcing agreement with Astellas to outsource one of its internal testing laboratories.

Actinium Pharmaceuticals and Astellas will collaborate on a radiopharmaceutical

Actinium Pharmaceuticals entered into a research and option agreement with Astellas Pharma to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology.

EMA accepts Astellas filing for review of prostate cancer drug

Astellas Pharma announced that the European Medicines Agency (EMA) has validated and started the review process for Astellas’ application for a Type II Variation for enzalutamide.

Astellas will set up a drug manufacturing in Turkey

Japanese pharmaceutical company Astellas has decided to manufacture medications in Gebze, Turkey. In the first stage, contract manufacturing will be discussed for the production of medication for urinary tract ailments.

Universal Cells becomes a subsidiary of Astellas

Astellas will gain Universal Cells' proprietary Universal Donor Cell technology to create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching

Astellas accomplished the acquisition of US biotech Mitobridge

Astellas Pharma Inc., a leading Japanese pharmaceutical company, announced that it has completed the acquisition of Mitobridge, Inc., and Mitobridge has become a wholly owned subsidiary of Astellas.

Astellas announced the acquisition of Mitobridge biotechnology company

Astellas Pharma and Mitobridge announced that Astellas has exercised its exclusive option right to acquire Mitobridge

Astellas pharma bought Ogeda SA

Astellas Pharma Inc. today announced that it has completed the acquisition of Ogeda SA